Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 2/20 | 0.48 |
| ▸ | LDHB | P07195 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20746571 | 1.00 | NPC1 (0.50) | NPC1RAB9ALDHALDHBKMT2A | |
| SCHEMBL20746235 | 0.90 | GAA (0.52) | RAB9ALDHALDHBKMT2AMEN1 | |
| SCHEMBL20746236 | 0.90 | GAA (0.52) | RAB9ALDHALDHBKMT2AMEN1 | |
| SCHEMBL20746446 | 0.89 | KMT2A (0.53) | NPC1RAB9ALDHALDHBKMT2A | |
| SCHEMBL20746448 | 0.89 | KMT2A (0.53) | NPC1RAB9ALDHALDHBKMT2A | |
| SCHEMBL20754505 | 0.87 | LDHA (0.51) | LDHALDHBKMT2AMAPTLMNA | |
| SCHEMBL22733793 | 0.87 | LDHA (0.51) | LDHALDHBKMT2AMAPTLMNA | |
| SCHEMBL20746472 | 0.87 | KMT2A (0.44) | NPC1RAB9ALDHALDHBKMT2A | |
| SCHEMBL20746471 | 0.87 | KMT2A (0.44) | NPC1RAB9ALDHALDHBKMT2A | |
| SCHEMBL28410857 | 0.84 | MAOB (0.50) | KMT2AMEN1MAPTALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385374-A1 | IMIDAZOLE-BASED ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | THE UNIVERSITY OF TOLEDO (US) | 2020-12-10 | — | — | US | claimed |
| US-20200385374-A1 | IMIDAZOLE-BASED ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | THE UNIVERSITY OF TOLEDO (US) | 2020-12-10 | — | — | US | disclosed |
| US-20200385374-A1 | IMIDAZOLE-BASED ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | THE UNIVERSITY OF TOLEDO (US) | 2020-12-10 | — | — | US | disclosed |
| WO-2019036607-A1 | IMIDAZOLE-BASED ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | THE UNIVERSITY OF TOLEDO (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036607-A1 | IMIDAZOLE-BASED ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | THE UNIVERSITY OF TOLEDO (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385374-A1 | IMIDAZOLE-BASED ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | HDAC1, HDAC8, HDAC2 | NPC1 1345/4885RAB9A 2894/4885LDHA 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.